|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 Biolargo, Inc. 10-Q 9/30/22 62:7.5M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.63M
2: EX-3.4 Articles of Incorporation/Organization or Bylaws HTML 21K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
5: EX-32 Certification -- §906 - SOA'02 HTML 21K
11: R1 Document And Entity Information HTML 69K
12: R2 Consolidated Balance Sheets (Current Period HTML 152K
Unaudited)
13: R3 Consolidated Balance Sheets (Current Period HTML 33K
Unaudited) (Parentheticals)
14: R4 Consolidated Statements of Operations and HTML 116K
Comprehensive Loss (Unaudited)
15: R5 Consolidated Statement of Stockholders' Equity HTML 138K
(Deficit) (Unaudited)
16: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 119K
17: R7 Note 1 - Business and Organization HTML 29K
18: R8 Note 2 - Summary of Significant Accounting HTML 115K
Policies
19: R9 Note 3 - Sale of Stock for Cash HTML 23K
20: R10 Note 4 - Debt Obligations HTML 47K
21: R11 Note 5 - Share-based Compensation HTML 115K
22: R12 Note 6 - Warrants HTML 51K
23: R13 Note 7 - Accounts Payable and Accrued Expenses HTML 27K
24: R14 Note 8 - Noncontrolling Interest - Clyra Medical HTML 43K
25: R15 Note 9 - Business Segment Information HTML 116K
26: R16 Note 10 - Commitments and Contingencies HTML 25K
27: R17 Note 11 - Subsequent Events HTML 23K
28: R18 Significant Accounting Policies (Policies) HTML 164K
29: R19 Note 2 - Summary of Significant Accounting HTML 83K
Policies (Tables)
30: R20 Note 4 - Debt Obligations (Tables) HTML 39K
31: R21 Note 5 - Share-based Compensation (Tables) HTML 96K
32: R22 Note 6 - Warrants (Tables) HTML 47K
33: R23 Note 7 - Accounts Payable and Accrued Expenses HTML 26K
(Tables)
34: R24 Note 8 - Noncontrolling Interest - Clyra Medical HTML 44K
(Tables)
35: R25 Note 9 - Business Segment Information (Tables) HTML 106K
36: R26 Note 1 - Business and Organization (Details HTML 56K
Textual)
37: R27 Note 2 - Summary of Significant Accounting HTML 66K
Policies (Details Textual)
38: R28 Note 2 - Summary of Significant Accounting HTML 23K
Policies - Summary of Cash Balances (Details)
39: R29 Note 2 - Summary of Significant Accounting HTML 39K
Policies - Credit Concentration (Details)
40: R30 Note 2 - Summary of Significant Accounting HTML 24K
Policies - Inventory (Details)
41: R31 Note 2 - Summary of Significant Accounting HTML 25K
Policies - Other Non-current Assets (Details)
42: R32 Note 2 - Summary of Significant Accounting HTML 39K
Policies - Stock Options, Valuation Assumptions
(Details)
43: R33 Note 3 - Sale of Stock for Cash (Details Textual) HTML 31K
44: R34 Note 4 - Debt Obligations (Details Textual) HTML 35K
45: R35 Note 4 - Debt Obligations - Schedule of Debt HTML 38K
(Details)
46: R36 Note 5 - Share-based Compensation (Details HTML 122K
Textual)
47: R37 Note 5 - Share-based Compensation - Stock Options HTML 81K
(Details)
48: R38 Note 6 - Warrants (Details Textual) HTML 39K
49: R39 Note 6 - Warrants - Warrants Outstanding (Details) HTML 43K
50: R40 Note 7 - Accounts Payable and Accrued Expenses - HTML 31K
Summary of Accounts Payable and Accrued Expenses
(Details)
51: R41 Note 8 - Noncontrolling Interest - Clyra Medical HTML 129K
(Details Textual)
52: R42 Note 8 - Noncontrolling Interest - Clyra Medical - HTML 27K
Common Shares Outstanding (Details)
53: R43 Note 8 - Noncontrolling Interest - Clyra Medical - HTML 27K
Summary of Accounts Payable and Accrued Expenses
(Details)
54: R44 Note 9 - Business Segment Information (Details HTML 19K
Textual)
55: R45 Note 9 - Business Segment Information - Segment HTML 79K
Information (Details)
56: R46 Note 10 - Commitments and Contingencies (Details HTML 36K
Textual)
57: R47 Note 11 - Subsequent Events (Details Textual) HTML 42K
60: XML IDEA XML File -- Filing Summary XML 113K
58: XML XBRL Instance -- blgo20220930_10q_htm XML 2.24M
59: EXCEL IDEA Workbook of Financial Reports XLSX 117K
7: EX-101.CAL XBRL Calculations -- blgo-20220930_cal XML 117K
8: EX-101.DEF XBRL Definitions -- blgo-20220930_def XML 1.15M
9: EX-101.LAB XBRL Labels -- blgo-20220930_lab XML 921K
10: EX-101.PRE XBRL Presentations -- blgo-20220930_pre XML 1.16M
6: EX-101.SCH XBRL Schema -- blgo-20220930 XSD 173K
61: JSON XBRL Instance as JSON Data -- MetaLinks 341± 540K
62: ZIP XBRL Zipped Folder -- 0001437749-22-027358-xbrl Zip 262K
EXHIBIT 31.2
Certification of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Charles K. Dargan II, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioLargo, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: November 14, 2022 |
By: |
|
|
Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/24 Biolargo, Inc. S-1 6:2M RDG Filings/FA 4/12/24 Biolargo, Inc. POS AM 5:1.8M RDG Filings/FA 4/12/24 Biolargo, Inc. POS AM 5:1.8M RDG Filings/FA 4/01/24 Biolargo, Inc. 10-K 12/31/23 79:9.5M RDG Filings/FA 11/14/23 Biolargo, Inc. 10-Q 9/30/23 68:8.8M RDG Filings/FA 8/14/23 Biolargo, Inc. 10-Q 6/30/23 67:8.6M RDG Filings/FA 5/17/23 Biolargo, Inc. 10-Q 3/31/23 70:8.3M RDG Filings/FA 4/27/23 Biolargo, Inc. S-1 5:1.9M RDG Filings/FA 4/27/23 Biolargo, Inc. POS AM 3:1.8M RDG Filings/FA 4/14/23 Biolargo, Inc. POS AM 4:1.8M RDG Filings/FA 3/31/23 Biolargo, Inc. 10-K 12/31/22 77:9.4M RDG Filings/FA 1/11/23 Biolargo, Inc. S-1/A 5:2.6M RDG Filings/FA 12/23/22 Biolargo, Inc. S-1 5:2.7M RDG Filings/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/21 Biolargo, Inc. 10-K 12/31/20 73:9.1M RDG Filings/FA 3/19/21 Biolargo, Inc. 8-K:1,9 3/18/21 2:44K RDG Filings/FA 8/14/20 Biolargo, Inc. 10-Q 6/30/20 61:7.4M RDG Filings/FA 7/07/20 Biolargo, Inc. 8-K:1,9 6/30/20 6:191K RDG Filings/FA 3/31/20 Biolargo, Inc. 8-K:1,9 3/30/20 3:419K RDG Filings/FA 2/27/20 Biolargo, Inc. 8-K:1,9 2/25/20 2:53K RDG Filings/FA 6/22/18 Biolargo, Inc. POS AM 3:2.8M RDG Filings/FA 6/22/18 Biolargo, Inc. S-8 6/22/18 8:502K RDG Filings/FA 5/14/18 Biolargo, Inc. 10-Q 3/31/18 68:6.2M RDG Filings/FA 8/24/16 Biolargo, Inc. 8-K:1,9 8/18/16 2:9.3M RDG Filings/FA 1/06/16 Biolargo, Inc. 8-K:3,8,9 12/30/15 7:462K RDG Filings/FA 3/31/15 Biolargo, Inc. 10-K 12/31/14 75:15M RDG Filings/FA 5/04/07 Biolargo, Inc. 10KSB 12/31/06 19:1.4M Donnelley … Solutions/FA 5/23/03 Biolargo, Inc. 10KSB 12/31/02 15:591K Toppan Merrill/FA |